Mantle Cell Lymphoma

Results from the WINDOW-1 signal promise for use of the R-HCVAD regimen in patients with mantle cell lymphoma.

Lori A. Leslie, MD, discusses her recent presentation around chimeric antigen receptor T-cell therapy for mantle cell lymphoma and indolent lymphomas.

Treatment of indolent mantle cell lymphoma tumors may require an individualize approach, but frontline ibrutinib and rituximab is one possibility.

Peter Martin, MD, discusses questions asked in regards to patient populations in a real-world study of treatment patterns and outcomes of mantle cell lymphoma.

In an interview with Targeted Oncology, Christopher Melani, MD, discussed the ongoing ViPOR study exploring a Bruton’s tyrosine kinase inhibitor and BCL2 inhibitor, and NF-κB survival pathway activating combination.

At the 63rd ASH Annual Meeting and Exposition, studies highlighted the promise of Bruton's tyrosine kinase inhibitors for the treatment of patients with mantle cell lymphoma and what oncologists should do after Bruton's tyrosine kinase inhibition.

National Cancer Institute expert, Christopher J. Melani, MD, discusses the synergy of 5 drugs that make up a targeted therapy regimen for patients with mantle cell lymphoma.

In an interview with Targeted Oncology, Michael Wang, MD, a professor in the department of lymphoma and myeloma at MD Anderson Cancer Center, discussed the safety, efficacy, and tolerability of acalabrutinib plus venetoclax and rituximab in mantle cell lymphoma.

Tycel Jovelle Phillips, MD, discussed the use of glofitamab in patients with R/R MCL who have failed BTK inhibitors in an interview with Targeted Oncology.

A study of zilovertamab in combination with ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma will be launched in the second quarter of 2022.

Tycel Phillips, MD, a clinical associate professor of hematology and medical oncology at the University of Michigan Health, discusses the mechanism of action of glofitamab in patients with mantle cell lymphoma.

In the community setting, brexucabtagene autoleucel shows efficacy in patients with relapsed/refractory mantle cell lymphoma.

The novel non-covalent BTK inhibitor pirtobrutinib has shown encouraging preclinical efficacy in addressing resistance to ibrutinib and venetoclax resistance in mantle cell lymphoma models cell lines.

Michael Wang, MD, discusses the growing awareness of chimeric antigen receptor T-cell therapy among community oncologists and patients with mantle cell lymphoma.

Ocular adnexal region involvement remains rare, presenting in only between 1% to 5% of mantle cell lymphoma cases.

The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss possible future developments with BTKi as therapy options in B-cell lymphomas.

Drs Shadman and Cohen introduce new data concerning a third-generation BTK inhibitor, pirtobrutinib, and discuss unmet needs in the B-cell malignancy landscape.

Management of relapsed or refractory disease is a highly relevant topic for patients with mantle cell lymphoma and the clinicians who treat them.

Michael Wang, MD, discusses the real-world efficacy of brexucabtagene autoleucel, the first chimeric antigen receptor T-cell therapy for the treatment of mantle cell lymphoma.

A study at MD Anderson Cancer Center aims to evaluate ixazomib and rituximab in patients with relapsed or refractory mantle cell lymphoma.

Luhua Wang, MD, discussed the impact that the approval of the CAR T-cell therapy brexucabtagene autoleucel has had on mantle cell lymphoma.

Drs Shadman and Cohen provide an overview of clinical trials utilizing the BTK inhibitor, ibrutinib, for B-cell lymphomas.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, introduce available BTK inhibitors used as targeted therapy in B-cell malignancies.

According to Tycel Jovelle Phillips, MD, the study of venetoclax in combination with the R2 regimen will be expanded to include 50 patients with mantle cell lymphoma without a TP53 mutation.